Apellis Pharmaceuticals, Inc.
APLSNASDAQHealthcare
$41.03
+$0.00(+0.00%)
Market Cap$5.3B
P/E Ratio—
52W High$41.14
52W Low$16.61
Apellis Pharmaceuticals, Inc. (APLS) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · APLS · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.02B | ($0.20B) | ($0.53B) | ($0.65B) | ($0.75B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.00B | $0.11B | $0.11B | $0.09B | $0.07B |
| Change in Working Capital | ($0.09B) | ($0.02B) | ($0.20B) | ($0.02B) | ($0.09B) |
| Net Cash from Operations | $0.05B | ($0.09B) | ($0.59B) | ($0.51B) | ($0.56B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | $0.00B | $0.00B | $0.00B | ($0.33B) | ($0.17B) |
| Sales of Investments | $0.00B | $0.00B | $0.00B | $0.39B | $0.42B |
| Net Cash from Investing | ($0.00B) | ($0.00B) | ($0.00B) | $0.06B | $0.25B |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.37B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.01B | $0.15B | $0.39B | $0.37B | $0.39B |
| Free Cash Flow | |||||
| Free Cash Flow | $0.05B | ($0.09B) | ($0.60B) | ($0.52B) | ($0.56B) |
| FCF Margin %(computed) | 4.48% | -11.30% | -150.16% | -683.18% | -847.66% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Apellis Pharmaceuticals, Inc. data
About Apellis Pharmaceuticals, Inc. (APLS) Cash Flow Statement
Apellis Pharmaceuticals, Inc. generated operating cash flow of $0.05B and free cash flow of $0.05B for 2025 — a FCF margin of 4.48%. Capital expenditure was ($0.00B).
Frequently asked questions
APLS · 4 questionsApellis Pharmaceuticals, Inc. generated free cash flow of $0.05B for 2025, up 151.0% year-over-year.
APLS free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10